IL130022A0 - Nefazodone dosage form - Google Patents
Nefazodone dosage formInfo
- Publication number
- IL130022A0 IL130022A0 IL13002299A IL13002299A IL130022A0 IL 130022 A0 IL130022 A0 IL 130022A0 IL 13002299 A IL13002299 A IL 13002299A IL 13002299 A IL13002299 A IL 13002299A IL 130022 A0 IL130022 A0 IL 130022A0
- Authority
- IL
- Israel
- Prior art keywords
- nefazodone
- dosage form
- dosage
- nefazodone dosage
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 title 1
- 229960001800 nefazodone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8821198P | 1998-06-05 | 1998-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL130022A0 true IL130022A0 (en) | 2000-02-29 |
Family
ID=22210038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13002299A IL130022A0 (en) | 1998-06-05 | 1999-05-19 | Nefazodone dosage form |
Country Status (20)
Country | Link |
---|---|
US (1) | US6143325A (pt) |
EP (1) | EP0966966A3 (pt) |
JP (1) | JP2000007567A (pt) |
KR (1) | KR20000005930A (pt) |
CN (1) | CN1238181A (pt) |
AR (1) | AR018862A1 (pt) |
AU (1) | AU3319999A (pt) |
BR (1) | BR9901782A (pt) |
CA (1) | CA2273546A1 (pt) |
CO (1) | CO5060477A1 (pt) |
HU (1) | HUP9901830A2 (pt) |
ID (1) | ID23458A (pt) |
IL (1) | IL130022A0 (pt) |
NO (1) | NO992692L (pt) |
NZ (1) | NZ336001A (pt) |
PE (1) | PE20000544A1 (pt) |
PL (1) | PL333524A1 (pt) |
SG (1) | SG77244A1 (pt) |
UY (1) | UY25544A1 (pt) |
ZA (1) | ZA993345B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143325A (en) * | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
EP1428535A1 (en) * | 1998-11-02 | 2004-06-16 | ALZA Corporation | Controlled delivery of antidepressants |
KR20070040421A (ko) * | 1998-11-02 | 2007-04-16 | 알자 코포레이션 | 항우울제의 제어된 전달 |
US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
AU2002306616A1 (en) * | 2001-03-02 | 2002-09-19 | Sepracor Inc. | Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine |
BR0205721A (pt) | 2001-07-06 | 2003-09-30 | Endo Pharmaceuticals Inc | Formulações de oximorfona de liberação controlada |
EP1404332A1 (en) | 2001-07-06 | 2004-04-07 | Penwest Pharmaceuticals Company | Methods of making sustained release formulations of oxymorphone related applications |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US20040220240A1 (en) * | 2001-11-28 | 2004-11-04 | Pellegrini Cara A. | Method of increasing the extent of absorption of tizanidine |
US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
US7714006B1 (en) | 2001-12-03 | 2010-05-11 | King Pharmaceuticals Research & Development, Inc. | Methods of modifying the bioavailability of metaxalone |
US6407128B1 (en) | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
US20050256131A1 (en) * | 2002-05-24 | 2005-11-17 | Carl-Fr Coester | Pharmaceutical active substance combination and the use thereof |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
GB0306604D0 (en) * | 2003-03-21 | 2003-04-30 | Curidium Ltd | Second medical use |
ES2336913T3 (es) * | 2003-08-08 | 2010-04-19 | Biovail Laboratories International Srl | Comprimido de liberacion modificada de hidrocloruro de bupropion. |
EP1732610A2 (en) * | 2004-03-26 | 2006-12-20 | Baylor University | Targeted serotonin reuptake inhibitors |
US8795723B2 (en) | 2005-09-09 | 2014-08-05 | Angelini Pharma Inc. | Sustained drug release compositions |
US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
WO2012072665A1 (en) | 2010-11-30 | 2012-06-07 | Pharmaneuroboost N.V. | Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors |
JP2011140510A (ja) * | 2011-03-17 | 2011-07-21 | Biovail Lab Inc | 塩酸ブプロピオンの放出調節錠剤 |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
JP6184903B2 (ja) * | 2014-06-04 | 2017-08-23 | ヴァレアント インターナショナル バミューダValeant International Bermuda | 塩酸ブプロピオン放出調節錠剤 |
JP6078514B2 (ja) * | 2014-10-30 | 2017-02-08 | コリア ユナイテッド ファーム,インク | 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4983398A (en) * | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5536507A (en) * | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
ATE236616T1 (de) * | 1995-09-29 | 2003-04-15 | Lam Pharmaceutical Corp | Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten |
AU3290397A (en) * | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
US6143325A (en) * | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
-
1999
- 1999-04-26 US US09/299,959 patent/US6143325A/en not_active Expired - Lifetime
- 1999-05-14 ZA ZA9903345A patent/ZA993345B/xx unknown
- 1999-05-19 IL IL13002299A patent/IL130022A0/xx unknown
- 1999-05-28 NZ NZ336001A patent/NZ336001A/xx unknown
- 1999-06-01 SG SG1999002831A patent/SG77244A1/en unknown
- 1999-06-02 PL PL99333524A patent/PL333524A1/xx not_active Application Discontinuation
- 1999-06-03 AR ARP990102618A patent/AR018862A1/es unknown
- 1999-06-03 CA CA002273546A patent/CA2273546A1/en not_active Abandoned
- 1999-06-03 HU HU9901830A patent/HUP9901830A2/hu unknown
- 1999-06-03 NO NO992692A patent/NO992692L/no not_active Application Discontinuation
- 1999-06-04 CO CO99035356A patent/CO5060477A1/es unknown
- 1999-06-04 EP EP99110777A patent/EP0966966A3/en not_active Withdrawn
- 1999-06-04 PE PE1999000481A patent/PE20000544A1/es not_active Application Discontinuation
- 1999-06-04 ID IDP990521D patent/ID23458A/id unknown
- 1999-06-04 UY UY25544A patent/UY25544A1/es not_active Application Discontinuation
- 1999-06-04 BR BR9901782-2A patent/BR9901782A/pt not_active IP Right Cessation
- 1999-06-04 AU AU33199/99A patent/AU3319999A/en not_active Abandoned
- 1999-06-04 JP JP11157499A patent/JP2000007567A/ja active Pending
- 1999-06-04 KR KR1019990020676A patent/KR20000005930A/ko not_active Application Discontinuation
- 1999-06-07 CN CN99108308A patent/CN1238181A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
BR9901782A (pt) | 2000-05-09 |
PE20000544A1 (es) | 2000-06-29 |
CO5060477A1 (es) | 2001-07-30 |
SG77244A1 (en) | 2000-12-19 |
EP0966966A3 (en) | 2000-02-09 |
AU3319999A (en) | 1999-12-16 |
AR018862A1 (es) | 2001-12-12 |
HUP9901830A2 (hu) | 2001-06-28 |
NO992692D0 (no) | 1999-06-03 |
HU9901830D0 (en) | 1999-07-28 |
ZA993345B (en) | 2000-08-22 |
PL333524A1 (en) | 1999-12-06 |
US6143325A (en) | 2000-11-07 |
UY25544A1 (es) | 2001-08-27 |
NO992692L (no) | 1999-12-06 |
ID23458A (id) | 2000-04-27 |
CN1238181A (zh) | 1999-12-15 |
NZ336001A (en) | 2000-09-29 |
CA2273546A1 (en) | 1999-10-10 |
KR20000005930A (ko) | 2000-01-25 |
JP2000007567A (ja) | 2000-01-11 |
EP0966966A2 (en) | 1999-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL130022A0 (en) | Nefazodone dosage form | |
GB9801363D0 (en) | Novel dosage form | |
HK1033649A1 (en) | Extended release dosage form | |
GB0029386D0 (en) | Not known at present | |
GB9817118D0 (en) | Pharmaceutical compounds | |
GB2357761B (en) | Compounds | |
HUP0203204A3 (en) | Oral dosage forms | |
GB9817623D0 (en) | Pharmaceutical compounds | |
GB0029389D0 (en) | Not known at present | |
GB9810886D0 (en) | Pharmaceutical compounds | |
GB0021654D0 (en) | Not available at present | |
GB9823847D0 (en) | Pharmaceutical compounds | |
GB9823845D0 (en) | Pharmaceutical compounds | |
GB9808665D0 (en) | Therapeutic compounds | |
GB9902399D0 (en) | Compounds | |
GB9824897D0 (en) | Therapeutic compounds | |
GB9817197D0 (en) | Pharmaceutical compounds | |
GB9827865D0 (en) | Medicament | |
GB9808667D0 (en) | Therapeutic compounds | |
GB9821694D0 (en) | Amphiphilogel dosage form | |
ZA989425B (en) | Dosage form | |
GB9828707D0 (en) | Pharmaceutical uses | |
HK1047232A1 (zh) | 口服劑型 | |
GB9815388D0 (en) | Pharmaceutical compounds | |
HUP9904478A3 (en) | Dosage device |